Has Allen Burris received payments from drug or device companies?

Yes. Drug and device makers reported $261,099 in general payments to Allen Burris across 667 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Allen Burris did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Allen Burris come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Allen Burris

Endocrinology, Diabetes & Metabolism · Powhatan, VANPI 1487646485

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $218,197 of the $261,099 with a category attached, or 83.6%. Novo Nordisk accounts for 63.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2019 at $88,848 and has fallen 98.4% since, to $1,394 in 2023. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$261,099in general payments, 2019–2025

Across 667 payments — averaging $391.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$166K
Lilly USA, LLC$36K
AstraZeneca$22K
Merck$17K
Clarus Therapeutics Inc.$8K
AbbVie$5K
plus $6K from 38 others

What the payments were for

Consulting fees$4,0002%
Speaking & faculty fees$218,19784%
Travel & lodging$26,64110%
Food & beverage$12,2345%
Education$270%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	205	$166,426
Lilly USA, LLC	99	$36,393
AstraZeneca	67	$21,557
Merck	36	$16,760
Clarus Therapeutics Inc.	16	$8,160
AbbVie	23	$5,457
Abbott	35	$2,061
Esperion Therapeutics, Inc.	5	$960
Amgen(2 entities)	37	$824
Antares Pharma, Inc.	19	$397
Sanofi-aventis U.S. LLC	12	$237
Amarin Pharma, Inc.	9	$157
Lifescan, Inc.	10	$148
Xeris Pharmaceuticals, Inc.	7	$145
Dexcom, Inc.	7	$135
IBSA Pharma Inc.	7	$132
Amneal Pharmaceuticals LLC	9	$128
Boehringer Ingelheim	7	$113
Shire North American Group Inc	9	$112
Kowa Pharmaceuticals America, Inc.	7	$100
Medtronic(2 entities)	5	$70
Insulet Corporation	3	$60
Valeritas, Inc.	2	$56
Zealand Pharma US, Inc.	3	$54
Pfizer	3	$53
Tandem Diabetes Care, Inc.	3	$44
Johnson & Johnson	3	$41
Regeneron Healthcare Solutions, Inc.	2	$35
Takeda Pharmaceuticals U.S.A., Inc.	2	$29
Recordati_rare_diseases_inc.	1	$23
Novartis	1	$20
Ipsen Biopharmaceuticals, Inc	1	$19
BD	1	$18
Vifor Pharma, Inc.	1	$18
Nalpropion Pharmaceuticals LLC	1	$18
Ultragenyx Pharmaceutical Inc.	1	$17
Amryt Pharma Holdings Ltd	1	$17
AMAG Pharmaceuticals, Inc.	1	$16
Metuchen Pharmaceuticals	1	$16
Mannkind Corporation	1	$15
Vistapharm, Inc.	1	$15
Aytu Biopharma, Inc.	1	$15
Currax Pharmaceuticals LLC	1	$14
Scilex Pharmaceuticals Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RYBELSUS$109,820
TRULICITY$33,155
Ozempic$32,326
JATENZO$23,699
FARXIGA$20,861
Tresiba$19,745
STEGLATRO$16,281
Synthroid$5,099
FreeStyle Libre Pro$1,650
NEXLIZET$900
NEXLETOL$900
EVENITY$122
Repatha$108

How this compares

$261,099 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia →

Other endocrinology, diabetes & metabolism in Powhatan

Farhad ZangenehSterling$1.2M
James MulindaRoanoke$788K
Jeffrey SicatGlen Allen$657K
Dewey BaileyRoanoke$645K
Domenica RubinoArlington$608K
Samamtha HudsonMidlothian$372K
Elias SirajNorfolk$316K
Samim EnayatFairfax$217K
Denise ArmelliniFairfax$152K
Ben PhillipsMidlothian$99K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →